# Effects of Sodium-Glucose Co-transporter 2 Inhibitors on Inflammation

> **NCT06812429** · EARLY_PHASE1 · COMPLETED · sponsor: **Washington University School of Medicine** · enrollment: 6 (actual)

## Conditions studied

- Inflammation

## Interventions

- **DRUG:** Dapagliflozin (DAPA)

## Key facts

- **NCT ID:** NCT06812429
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-05-08
- **Primary completion:** 2025-04-05
- **Final completion:** 2025-04-05
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2026-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06812429

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06812429, "Effects of Sodium-Glucose Co-transporter 2 Inhibitors on Inflammation". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06812429. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*